No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating within India, Mangalam Drugs & Organics Limited specializes in the production and distribution of active pharmaceutical ingredients (APIs) and various chemical intermediates. Its extensive catalog of API offerings encompasses medications such as Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium. The company also provides Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin in both Anhydrous and Monohydrate forms; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; alongside Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. Furthermore, the firm supplies chemical intermediates like 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and the base forms of Tenofovir Alafenamide and Disoproxil. Its product portfolio is further diversified with specialty chemicals, including Menthol, 2,3-Dihydrophthalazine-1, 4-dione, and 4-cynoethyl-2-methyl phenol. Looking to the future, Mangalam Drugs & Organics is actively developing new pharmaceutical compounds, such as Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir. Its development pipeline also features Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. Established in 1972, the company maintains its headquarters in Mumbai, India.
www.mangalamdrugs.comNo one on the platform currently holds MANGALAM.BO.
No tracked institution reports a position in MANGALAM.BO as of their last filing.
No one on the platform has traded MANGALAM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MANGALAM.BOMangalam Drugs & Organics Limited | $32.55 | -2.22% | $508M | — |
| BALPHARMA.BOBal Pharma Limited | $101.75 | -5.23% | $1.6B | — |
| BALPHARMA.NSBal Pharma Limited | $102.05 | -5.02% | $1.6B | — |
| BIBCL.BOBharat Immunologicals & Biologicals Corporation Limited | $14.75 | -0.47% | $637M | — |
| JSTL.BOJeevan Scientific Technology Limited | $79.90 | -1.36% | $1.6B | — |
| KREBSBIO.BOKrebs Biochemicals & Industries Limited | $56.05 | -1.08% | $1.2B | — |
| KREBSBIO.NSKrebs Biochemicals & Industries Limited | $56.40 | +0.23% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry